{"id":342,"date":"2013-12-13T09:07:20","date_gmt":"2013-12-13T09:07:20","guid":{"rendered":"https:\/\/sagaciousresearch.com\/blog\/?p=342"},"modified":"2022-09-26T06:01:10","modified_gmt":"2022-09-26T06:01:10","slug":"bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir","status":"publish","type":"post","link":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir","title":{"rendered":"BMS &#038; Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d"},"content":{"rendered":"\n<p>By 2016, there will be approx. 1 M HIV patients who will need second-line AIDS treatment as offered by Bristol-Myers Squibb\u2019s HIV drug, \u201cAtazanavir\u201d (brand name Reyataz). Taking that in serious consideration, BMS has agreed to enter a joint patent licensing program with United Nations-backed Medicines Patent Pool (MPP) and share intellectual property rights of this vital HIV\/AIDS drug.<\/p>\n\n\n\n<p>The agreement was announced on 12 December, 2013. It will enable generic drug firms around the world to produce Atazanavir\u2019s affordable versions thereby making AIDS treatment widely and easily available in poor countries. The Medicines Patent Pool offers a public-health driven business model that aims to lower the prices of HIV medicines and facilitate the development of better-adapted HIV medicines in developing countries. It was founded in 2010 through the WHO-based financing mechanism UNITAID.<\/p>\n\n\n\n<p><strong>Medicines Patent Pool\u2019s Other Agreements:<\/strong><\/p>\n\n\n\n<p>\u2022 &nbsp;Back in August 2013, MPP and Roche have entered an agreement to increase access to valganciclovir, a key oral medicine to treat cytomegalovirus (CMV), a viral infection that can cause blindness in people living with HIV.<\/p>\n\n\n\n<p>\u2022 MPP also collaborated with ViiV Healthcare \u2013 a joint venture of GlaxoSmithKline, Pfizer, and Shionogi to facilitate greater availability of key pediatric HIV medicine, abacavir.<\/p>\n\n\n\n<p><strong>Patent Pools:<\/strong><br>It is a consortium of at least two companies who have decided to offer a joint license for their patents that are essential to the practice of a defined specification. In simple words, it is a joint licensing program where a number of firms pool all their relevant patents that pertain to a particular technology\/specification.<\/p>\n\n\n\n<p><strong>Benefits<\/strong> &#8211; &nbsp;Patent pools are exemplary in the sense that they unite the members of an otherwise competitive industry to join a common cause to create some resource that is to their collective benefit. The other benefits of patent pools are-<\/p>\n\n\n\n<p>\u2022 Helps in the deployment of new technologies to the marketplace and set a market rate for Essential Patents. This encourages licensors to join the program and encourages licensees to obtain license. Thus, it saves time and effort in getting access to some Essential Patents<\/p>\n\n\n\n<p>\u2022 Helps in integrating complementary technologies and reduce transaction costs for both licensors and licensees thereby removing any uncertainty about the availability of patent licenses and their costs<\/p>\n\n\n\n<p>\u2022 Besides saving transaction costs for both licensee and patentee, in case of blocking patents, patent pools are possibly the only reasonable method for making the invention available in the public domain.<\/p>\n\n\n\n<p>\u2022 Patent pools do not completely eliminate risk. However, if patent holders (of other patent pools) and those outside the pool pose threat of a patent infringement lawsuit, being a part of a patent pool does help as all its member share common interests.<\/p>\n\n\n\n<p><strong>Our Services:<\/strong><br><strong><a href=\"https:\/\/sagaciousresearch.com\/patent-licensing-monetization\">Patent Licensing<\/a><\/strong> Group&nbsp;|<strong>&nbsp;<a href=\"https:\/\/sagaciousresearch.com\/india-ip-litigation-support\">Patent Litigation Services<\/a><\/strong>&nbsp;|&nbsp;<strong><a href=\"https:\/\/patentdraftingcatalyst.com\/\">Patent Drafting Rights<\/a> <\/strong>|<a href=\"https:\/\/sagaciousresearch.com\/patent-docketing\"> <strong>Patent Docketing <\/strong><\/a>| <strong><a href=\"https:\/\/sagaciousresearch.com\/patentability-search\">Patent Novelty<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By 2016, there will be approx. 1 M HIV patients who will need second-line AIDS treatment as offered by Bristol-Myers Squibb\u2019s HIV drug, \u201cAtazanavir\u201d (brand name Reyataz). Taking that in serious consideration, BMS has&#46;&#46;&#46;<\/p>\n","protected":false},"author":1,"featured_media":25863,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"coauthors":[983],"class_list":["post-342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BMS &amp; Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d - Sagacious IP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS &amp; Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d - Sagacious IP\" \/>\n<meta property=\"og:description\" content=\"By 2016, there will be approx. 1 M HIV patients who will need second-line AIDS treatment as offered by Bristol-Myers Squibb\u2019s HIV drug, \u201cAtazanavir\u201d (brand name Reyataz). Taking that in serious consideration, BMS has&#046;&#046;&#046;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir\" \/>\n<meta property=\"og:site_name\" content=\"Sagacious IP\" \/>\n<meta property=\"article:published_time\" content=\"2013-12-13T09:07:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-26T06:01:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2100\" \/>\n\t<meta property=\"og:image:height\" content=\"1400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Vilas Karnake\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vilas Karnake\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#article\",\"isPartOf\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir\"},\"author\":{\"name\":\"Vilas Karnake\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/ee18415b4ec48919d929dd9732c9749f\"},\"headline\":\"BMS &#038; Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d\",\"datePublished\":\"2013-12-13T09:07:20+00:00\",\"dateModified\":\"2022-09-26T06:01:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir\"},\"wordCount\":470,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#primaryimage\"},\"thumbnailUrl\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg\",\"articleSection\":[\"Articles\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir\",\"name\":\"BMS & Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d - Sagacious IP\",\"isPartOf\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#primaryimage\"},\"image\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#primaryimage\"},\"thumbnailUrl\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg\",\"datePublished\":\"2013-12-13T09:07:20+00:00\",\"dateModified\":\"2022-09-26T06:01:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#primaryimage\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg\",\"contentUrl\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg\",\"width\":2100,\"height\":1400,\"caption\":\"medicines-patent\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sagaciousresearch.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMS &#038; Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#website\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/\",\"name\":\"Sagacious IP\",\"description\":\"Blog\",\"publisher\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sagaciousresearch.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#organization\",\"name\":\"Sagacious IP\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2022\/06\/cropped-cropped-cropped-sagacious-ip-logo80-1-1.png\",\"contentUrl\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2022\/06\/cropped-cropped-cropped-sagacious-ip-logo80-1-1.png\",\"width\":481,\"height\":80,\"caption\":\"Sagacious IP\"},\"image\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/ee18415b4ec48919d929dd9732c9749f\",\"name\":\"Vilas Karnake\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/image\/d7edb6a9166e3680603701ae9e10e107\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/363be32d5f469b83f76184b09a333c02c746a62144121a8dcfc89b20ff076462?s=96&d=initials&r=g&initials=vk\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/363be32d5f469b83f76184b09a333c02c746a62144121a8dcfc89b20ff076462?s=96&d=initials&r=g&initials=vk\",\"caption\":\"Vilas Karnake\"},\"url\":\"https:\/\/sagaciousresearch.com\/blog\/author\/adm.vkarnake\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BMS & Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d - Sagacious IP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir","og_locale":"en_US","og_type":"article","og_title":"BMS & Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d - Sagacious IP","og_description":"By 2016, there will be approx. 1 M HIV patients who will need second-line AIDS treatment as offered by Bristol-Myers Squibb\u2019s HIV drug, \u201cAtazanavir\u201d (brand name Reyataz). Taking that in serious consideration, BMS has&#46;&#46;&#46;","og_url":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir","og_site_name":"Sagacious IP","article_published_time":"2013-12-13T09:07:20+00:00","article_modified_time":"2022-09-26T06:01:10+00:00","og_image":[{"width":2100,"height":1400,"url":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg","type":"image\/jpeg"}],"author":"Vilas Karnake","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Vilas Karnake","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#article","isPartOf":{"@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir"},"author":{"name":"Vilas Karnake","@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/ee18415b4ec48919d929dd9732c9749f"},"headline":"BMS &#038; Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d","datePublished":"2013-12-13T09:07:20+00:00","dateModified":"2022-09-26T06:01:10+00:00","mainEntityOfPage":{"@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir"},"wordCount":470,"commentCount":0,"publisher":{"@id":"https:\/\/sagaciousresearch.com\/blog\/#organization"},"image":{"@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#primaryimage"},"thumbnailUrl":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg","articleSection":["Articles"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir","url":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir","name":"BMS & Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d - Sagacious IP","isPartOf":{"@id":"https:\/\/sagaciousresearch.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#primaryimage"},"image":{"@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#primaryimage"},"thumbnailUrl":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg","datePublished":"2013-12-13T09:07:20+00:00","dateModified":"2022-09-26T06:01:10+00:00","breadcrumb":{"@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#primaryimage","url":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg","contentUrl":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/08-1.jpg","width":2100,"height":1400,"caption":"medicines-patent"},{"@type":"BreadcrumbList","@id":"https:\/\/sagaciousresearch.com\/blog\/bms-medicines-patent-pool-collaborates-over-hiv-drug-atazanavir#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sagaciousresearch.com\/blog\/"},{"@type":"ListItem","position":2,"name":"BMS &#038; Medicines Patent Pool Collaborates Over HIV Drug \u201cAtazanavir\u201d"}]},{"@type":"WebSite","@id":"https:\/\/sagaciousresearch.com\/blog\/#website","url":"https:\/\/sagaciousresearch.com\/blog\/","name":"Sagacious IP","description":"Blog","publisher":{"@id":"https:\/\/sagaciousresearch.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sagaciousresearch.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/sagaciousresearch.com\/blog\/#organization","name":"Sagacious IP","url":"https:\/\/sagaciousresearch.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2022\/06\/cropped-cropped-cropped-sagacious-ip-logo80-1-1.png","contentUrl":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2022\/06\/cropped-cropped-cropped-sagacious-ip-logo80-1-1.png","width":481,"height":80,"caption":"Sagacious IP"},"image":{"@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/ee18415b4ec48919d929dd9732c9749f","name":"Vilas Karnake","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/image\/d7edb6a9166e3680603701ae9e10e107","url":"https:\/\/secure.gravatar.com\/avatar\/363be32d5f469b83f76184b09a333c02c746a62144121a8dcfc89b20ff076462?s=96&d=initials&r=g&initials=vk","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/363be32d5f469b83f76184b09a333c02c746a62144121a8dcfc89b20ff076462?s=96&d=initials&r=g&initials=vk","caption":"Vilas Karnake"},"url":"https:\/\/sagaciousresearch.com\/blog\/author\/adm.vkarnake"}]}},"_links":{"self":[{"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/posts\/342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/comments?post=342"}],"version-history":[{"count":6,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/posts\/342\/revisions"}],"predecessor-version":[{"id":25864,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/posts\/342\/revisions\/25864"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/media\/25863"}],"wp:attachment":[{"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/media?parent=342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/tags?post=342"},{"taxonomy":"categories","embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=342"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/coauthors?post=342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}